

“Zintus[®] Tablets 25 mg/50 mg” Approved for Hypozincemia

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo/Managing Director & CEO: Jin Shiomura) announced that its hypozincemia treatment “Zintus[®] Tablets 25 mg/50 mg” (generic name: zinc histidine hydrate) (this “Product”) has been approved.

Zinc, as an essential trace element in the body, is required for the activity of many enzymes indispensable in vital function and fulfills diverse roles depending on various clinical states and conditions.

Hypozincemia is the zinc-deficient condition as serum zinc concentration decreases. Insufficient zinc is known to induce many different symptoms such as impaired taste, dermatitis, hair loss, anemia, oral inflammation, gonadal dysfunction, increased susceptibility to infection, pressure ulcer, loss of appetite, and developmental disturbance (pediatric).

“NOBELZIN[®] Tablets 25 mg/50mg/granules 5%” has already been on market for hypozincemia treatment, and this Product was approved based on the results of the comparative study with the NOBELZIN tablets. Better drug adherence is expected with this Product because it enables to supplement lost zinc with once-a-day dosage.

We hope the approval of this Product will be of some help by providing a new option for zinc supplementation therapy.

We are determined to continue contribution to society by providing critical but neglected pharmaceuticals and medical devices.

[Contact for Inquiries]

Noboru Kudo, Head of Communications

Nobelpharma Co., Ltd.

1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800